Health Catalyst

Modular AI Solutions Will Transform Value-Based Healthcare

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Mar 25

Updated

11 Dec 25

Views

24

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-69.3%

7D

-10.0%

Loading

1Y

-69.3%

7D

-10.0%

You can edit this narrative until Dec 12 11:10 PM. Then, changes will post as Updates.

Author's Valuation

US$3.9440.4% undervalued

AnalystConsensusTarget Fair Value

Shared on 11 Dec 25

HCAT: Stable Margins And Revenue Outlook Will Support Future Upside Potential

Narrative Update on Health Catalyst Analyst Price Target Analysts have modestly raised their price target on Health Catalyst by approximately 4 percent to around 3.94 dollars. This reflects slight adjustments to the discount rate and future earnings expectations, while views on revenue growth and profit margins remain largely unchanged.

Shared on 27 Nov 25

HCAT: Customer Partnerships Will Support Performance Despite Revised 2025 Revenue Outlook

Analysts have modestly lowered their price target for Health Catalyst. This adjustment is due to a slightly reduced profit margin outlook and a more conservative future price-to-earnings ratio, reflecting updated expectations for the company’s financial performance.

Shared on 13 Nov 25

Fair value Decreased 13%

HCAT: Ongoing Customer Relationships Will Drive Performance Amid Lower Revenue Guidance

Analysts have lowered their price target for Health Catalyst from $8 to $4. They cite recent reductions in revenue guidance, as well as expectations for lower growth and profitability.

Shared on 30 Aug 25

Fair value Decreased 15%

Health Catalyst's price target has been cut as analysts cite persistent operating headwinds, declining revenue outlook, customer churn, market structural challenges, and heightened uncertainty from a CEO transition, resulting in a downward revision of fair value from $5.33 to $4.56. Analyst Commentary Weak first-half 2025 bookings and a reduction in revenue guidance, implicating lower net revenue retention and increased customer churn.

Shared on 10 Aug 25

Fair value Decreased 23%

Health Catalyst’s consensus price target has been reduced to $5.78, primarily reflecting a deterioration in net profit margin despite a lower discount rate. What's in the News CEO Dan Burton will step down effective June 2026, transitioning from his full-time role while continuing to assist the Board and serve as a director.

Shared on 01 May 25

Fair value Increased 12%

Shared on 24 Apr 25

Fair value Decreased 27%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on 17 Apr 25

Fair value Decreased 4.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 28%

AnalystConsensusTarget has increased profit margin from 12.2% to 14.7%, decreased future PE multiple from 20.0x to 17.1x and increased discount rate from 9.9% to 11.0%.

Shared on 02 Apr 25

Fair value Decreased 4.32%

AnalystConsensusTarget Fair Value

US$3.94

40.4% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

-0.35%

Healthtech revenue growth rate

12.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

10.98%

Calculation

US$22.67m

Earnings '28

x

16.99x

PE Ratio '28

=

US$385.09m

Market Cap '28

US$385.09m

Market Cap '28

/

72.31m

No. shares '28

=

US$5.33

Share Price '28

US$5.33 Share Price '28

Discounted to 2025 @ 10.68% p.a.

=

US$3.93

Fair Value '25